Faeth Therapeutics has filed a notice of an exempt offering of securities to raise $24,999,993.00 in New Funding.
According to filings with the U.S. Securities and Exchange Commission, Faeth Therapeutics is raising up to $24,999,993.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Faeth Therapeutics
Faeth was born from three leading research teams with three separate discoveries coming together around one big idea: We can use metabolism to beat cancer. Cancer therapies have remained largely unchanged for decades. At Faeth, we believe that the use of metabolism will be a foundational treatment for cancer. Faeth is a data-driven, evidence-based company with a deep mechanistic understanding of the way that nutrients influence tumor growth and cancer treatment. Our discovery platform matches tumor genotypes with treatment regimens combining therapeutic targets and precision metabolic optimization to improve patient outcomes.
To learn more about Faeth Therapeutics, visit https://www.faeththerapeutics.com/
Faeth Therapeutics Linkedin Page: https://www.linkedin.com/company/faeththerapeutics/
Contact:
Anand Parikh, Chief Executive Officer
510-858-1839
https://www.linkedin.com/in/anandkparikh/
SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.
